Lixte’s CEO Bas van der Baan presented at MedInvest Biotech and Pharma Conference, April 3-4, […]

LIXTE Biotechnology Holdings Provides Update on Progress with Proprietary LB-100 Compound to Enhance Chemotherapy and […]

Researchers at the National Institute of Health as well as the Netherlands Cancer Institute and […]